Efficacy of Siponimod in Managing Relapsing-Remitting Multiple Sclerosis: Insights from a Real-World Cohort Study in a Chinese Center - Takeaways - MDSpire

Efficacy of Siponimod in Managing Relapsing-Remitting Multiple Sclerosis: Insights from a Real-World Cohort Study in a Chinese Center

  • By

  • Hongmei Tan

  • Lei Zhou

  • Yue Gao

  • Chongbo Zhao

  • Chuanzhen Lu

  • Qiang Dong

  • Jingzi ZhangBao

  • Chao Quan

  • February 18, 2026

  • 0 min

Share

  • 1

    Siponimod is a sphingosine-1-phosphate receptor modulator approved in China for treating relapsing-remitting and active secondary progressive multiple sclerosis.

  • 2

    The EXPAND trial demonstrated that siponimod significantly reduces the risk of confirmed disability progression in secondary progressive MS patients.

  • 3

    This study analyzed the effectiveness and safety of siponimod in a real-world cohort of 77 Chinese patients with relapsing-remitting multiple sclerosis.

  • 4

    Primary outcomes included annualized relapse rate, EDSS score changes, MRI activity, and no evidence of disease activity status.

  • 5

    The study aimed to provide insights into siponimod's performance in early relapsing MS, a population rarely investigated in previous research.

Original Source(s)

Efficacy of Siponimod in Managing Relapsing-Remitting Multiple Sclerosis: Insights from a Real-World Cohort Study in a Chinese Center

  • by Hongmei Tan, Lei Zhou, Yue Gao, Chongbo Zhao, Chuanzhen Lu, Qiang Dong, Jingzi ZhangBao, Chao Quan

  • February 18, 2026

Related Content

Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis: Benefits of Home-Based Self-Administration of Subcutaneous Ofatumumab Compared to Other High-Efficacy Treatments

Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses

Hippocampal neuronal hypoexcitability contributes to PTSD-like phenotypes in the experimental autoimmune encephalomyelitis model